168 related articles for article (PubMed ID: 16893995)
21. Conjugate vaccines against group B Streptococcus types IV and VII.
Paoletti LC; Kasper DL
J Infect Dis; 2002 Jul; 186(1):123-6. PubMed ID: 12089673
[TBL] [Abstract][Full Text] [Related]
22. Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide.
Nilo A; Passalacqua I; Fabbrini M; Allan M; Usera A; Carboni F; Brogioni B; Pezzicoli A; Cobb J; Romano MR; Margarit I; Hu QY; Berti F; Adamo R
Bioconjug Chem; 2015 Aug; 26(8):1839-49. PubMed ID: 26230938
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII.
Paoletti LC; Pinel J; Johnson KD; Reinap B; Ross RA; Kasper DL
J Infect Dis; 1999 Sep; 180(3):892-5. PubMed ID: 10438388
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.
Paoletti LC; Kennedy RC; Chanh TC; Kasper DL
Infect Immun; 1996 Feb; 64(2):677-9. PubMed ID: 8550227
[TBL] [Abstract][Full Text] [Related]
26. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity.
Laferrière CA; Sood RK; de Muys JM; Michon F; Jennings HJ
Vaccine; 1997 Feb; 15(2):179-86. PubMed ID: 9066036
[TBL] [Abstract][Full Text] [Related]
27. Designer vaccines to prevent infections due to group B Streptococcus.
Kasper DL
Proc Assoc Am Physicians; 1995 Oct; 107(3):369-73. PubMed ID: 8608425
[TBL] [Abstract][Full Text] [Related]
28. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
Madoff LC; Paoletti LC; Tai JY; Kasper DL
J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
[TBL] [Abstract][Full Text] [Related]
29. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
Paoletti LC; Rench MA; Kasper DL; Molrine D; Ambrosino D; Baker CJ
Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
[TBL] [Abstract][Full Text] [Related]
30. Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines.
Lockyer K; Gao F; Derrick JP; Bolgiano B
Vaccine; 2015 Mar; 33(11):1345-52. PubMed ID: 25640334
[TBL] [Abstract][Full Text] [Related]
31. Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation.
Pannaraj PS; Edwards MS; Ewing KT; Lewis AL; Rench MA; Baker CJ
Vaccine; 2009 Jul; 27(33):4452-6. PubMed ID: 19490960
[TBL] [Abstract][Full Text] [Related]
32. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.
Jennings HJ; Lugowski C
J Immunol; 1981 Sep; 127(3):1011-8. PubMed ID: 6790606
[TBL] [Abstract][Full Text] [Related]
33. Conjugation of Meningococcal Lipooligosaccharides Through Their Non-Reducing Terminus Results in Improved Induction a Protective Immune Response.
Mieszała M; Jennings HJ; Drab M; Gamian A
Arch Immunol Ther Exp (Warsz); 2019 Aug; 67(4):237-248. PubMed ID: 31030218
[TBL] [Abstract][Full Text] [Related]
34. Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.
Cheng Q; Debol S; Lam H; Eby R; Edwards L; Matsuka Y; Olmsted SB; Cleary PP
Infect Immun; 2002 Nov; 70(11):6409-15. PubMed ID: 12379721
[TBL] [Abstract][Full Text] [Related]
35. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
Yang HH; Mascuch SJ; Madoff LC; Paoletti LC
Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225
[TBL] [Abstract][Full Text] [Related]
36. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate.
Paoletti LC; Pinel J; Kennedy RC; Kasper DL
J Infect Dis; 2000 Feb; 181(2):653-8. PubMed ID: 10669351
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE
Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445
[TBL] [Abstract][Full Text] [Related]
38. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Edwards MS; Kasper DL
J Infect Dis; 2004 Mar; 189(6):1103-12. PubMed ID: 14999615
[TBL] [Abstract][Full Text] [Related]
39. Specificity and protective activity of murine monoclonal antibodies directed against the capsular polysaccharide of type III group B streptococci.
Teti G; Calapai M; Calogero G; Tomasello F; Mancuso G; Galli A; Riggio G
Hybridoma; 1992 Feb; 11(1):13-22. PubMed ID: 1371105
[TBL] [Abstract][Full Text] [Related]
40. Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope.
Michon F; Huang CH; Farley EK; Hronowski L; Di J; Fusco PC
Dev Biol (Basel); 2000; 103():151-60. PubMed ID: 11214233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
